On Aug. 27, 2020, Laurent Pharmaceuticals announced that it had received approval from the U.S. Food and Drug Administration (FDA) to start enrolling U.S. patients in RESOLUTION, a multicentric Phase 2 randomized placebo-controlled trial testing once-a-day oral LAU-7b as a potential treatment against COVID-19 disease.

RESOLUTION planned to enroll approximately 200 hospitalized COVID-19 patients who received either LAU-7B or a placebo for a treatment duration of 14 days.